{
  "ticker": "SNDX",
  "company_name": "Syndax Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05360160",
      "title": "A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Acute Myeloid Leukemia",
      "start_date": "2022-10-14",
      "completion_date": "2026-12-01",
      "enrollment": 0,
      "sponsor": "M.D. Anderson Cancer Center"
    },
    {
      "nct_id": "NCT03024437",
      "title": "Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Metastatic Cancer, Renal Cancer",
      "start_date": "2017-06-29",
      "completion_date": "2024-06-24",
      "enrollment": 0,
      "sponsor": "Roberto Pili"
    },
    {
      "nct_id": "NCT03501381",
      "title": "High Dose IL 2 and Entinostat in RCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Renal Cell Carcinoma",
      "start_date": "2018-05-24",
      "completion_date": "2024-04",
      "enrollment": 0,
      "sponsor": "Roberto Pili"
    }
  ],
  "summary": {
    "total_trials": 3,
    "by_phase": {
      "PHASE1, PHASE2": 2,
      "PHASE2": 1
    },
    "by_status": {
      "RECRUITING": 1,
      "TERMINATED": 1,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 2,
    "completed_trials": 0,
    "conditions": [
      "Acute Myeloid Leukemia",
      "Metastatic Cancer, Renal Cancer",
      "Renal Cell Carcinoma"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:55.037476",
    "search_query": "Syndax Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Syndax+Pharmaceuticals,+Inc."
  }
}